An international study including Australian patients has confirmed the long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. In the COLUMBA study, an open label extension of patients previously enrolled in the DREAM study, 347 patients received 100mg subcutaneous mepolizumab every four weeks for an average of 3.5 years. The humanised monoclonal ...
Already a member?
Enter your email to keep reading.